The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT02879539




Registration number
NCT02879539
Ethics application status
Date submitted
21/08/2016
Date registered
25/08/2016
Date last updated
25/08/2016

Titles & IDs
Public title
Cochlear Implant Low Power Strategy
Scientific title
Clinical Assessment of a Low Power Strategy for Cochlear Implant Recipients
Secondary ID [1] 0 0
CRC5607
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hearing Loss 0 0
Condition category
Condition code
Ear 0 0 0 0
Deafness

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - MP3000 sound coding strategy or ACE strategy with lower stimulation

Experimental: MP3000-ACE strategy - MP3000 sound coding strategy or ACE strategy with lower stimulation rate


Treatment: Devices: MP3000 sound coding strategy or ACE strategy with lower stimulation


Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Word recognition scores in quiet - Word recognition scores in quiet for i) MP3000 strategy compared to default ACE strategy and ii) lower rate stimulation for ACE strategy
Timepoint [1] 0 0
Testing over 18 weeks
Primary outcome [2] 0 0
Sentence recognition scores in quiet - Sentence recognition scores in quiet for i) MP3000 strategy compared to ACE strategy and ii) lower rate stimulation for ACE strategy
Timepoint [2] 0 0
Testing over 18 weeks
Secondary outcome [1] 0 0
Fundamental frequency (F0) discrimination - F0 discrimination for MP3000 strategy compared to the ACE baseline
Timepoint [1] 0 0
Testing over 18 weeks
Secondary outcome [2] 0 0
Speech intelligibility and helpfulness subjective ratings - For MP3000 strategy compared to the default ACE baseline
Timepoint [2] 0 0
Testing over 18 weeks
Secondary outcome [3] 0 0
Sentence in noise scores - Comparison of MP3000 program with Spatial NR and NR3 enabled versus disabled.
Timepoint [3] 0 0
Testing over 18 weeks

Eligibility
Key inclusion criteria
1. Adult (>18 years) cochlear implant recipients

2. Implanted with the CI500, CI24RE and Nucleus 24 Series and CI422 cochlear implants.

3. User of commercially available Freedom, CP810 or CP900 series sound processor

4. User of the ACE strategy or MP3000 strategy

5. At least 3 months experience with the cochlear implant

6. Native speaker in the language used to assess speech perception performance

7. Willingness to participate in and to comply with all requirements of the protocol
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Additional handicaps that would prevent participation in evaluations

2. Unrealistic expectations on the part of the subject, regarding the possible benefits,
risks and limitations that are inherent to the procedure and investigational device

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Unknown status
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
The HEARing CRC - Melbourne
Recruitment postcode(s) [1] 0 0
3002 - Melbourne

Funding & Sponsors
Primary sponsor type
Other
Name
The Hearing Cooperative Research Centre
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Royal Victoria Eye and Ear Hospital
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Commercial sector/Industry
Name [2] 0 0
Cochlear
Address [2] 0 0
Country [2] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Reducing power consumption in the cochlear implant is crucial to the development of future
smaller sound processors. The commercial MP3000 sound coding strategy has been shown to be
more efficient in power consumption to the standard ACE strategy. However in order to develop
smaller sound processors, further battery life power savings are required. The aim of this
study is to evaluate three experimental sets of MP3000 parameter sets, compared against the
default ACE program. In the background for each of the four strategies, experimental noise
reduction programs (SpatialNR and NR3) will also be in use. In an additional phase of the
study, low stimulation rate ACE programs will also be evaluated against the default
stimulation rate.
Trial website
https://clinicaltrials.gov/show/NCT02879539
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Robert Cowan, PhD, MBA
Address 0 0
Country 0 0
Phone 0 0
+613 9035 5346
Fax 0 0
Email 0 0
rcowan@hearingcrc.org
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT02879539